Navigation Links
Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting
Date:12/9/2007

- MGCD0103 Continues to Demonstrate Single-Agent Activity - 38% Response Rate, 43% Disease Control Rate and 86% Tumor Reduction Rate in Heavily-Pretreated Patients with Relapsed or Refractory Hodgkin Lymphoma

in 110mg Cohort - 67% Tumor Reduction Rate in Relapsed or Refractory Non-Hodgkin Lymphoma, Including an 18% Response Rate in Evaluable Diffuse Large B- cell Patients

ATLANTA, Dec. 9 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) and MethylGene Inc. (TSX: MYG) today announced data from two ongoing Phase 2 studies with MGCD0103, the Companies' novel, isotype-selective histone deacetylase (HDAC) inhibitor, as a single-agent in the treatment of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Data from these studies were presented today at the 49th Annual Meeting and Exposition of the American Society of Hematology (ASH).

"These exploratory Phase 2 trials show meaningful activity of MGCD0103 in patients with differing types of lymphomas," said Patrick J. Mahaffy, president and chief executive officer of Pharmion. "This is important not only for the continuing development of MGCD0103 but also because it provides further evidence for the role of epigenetic therapies in the treatment of hematologic malignancies."

"Data from these most recent trials continue to demonstrate the single- agent potential for MGCD0103 in a patient population that currently has few effective therapeutic options," said Donald F. Corcoran, president and chief executive officer of MethylGene. "With our partners, we will continue to evaluate our current and near-term MGCD0103 clinical trials during 2008 with the goal to develop a potential registrational pathway."

Isotype Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin lymphoma (HL), Abstract #2566 (Trial 010)

To date, 33 patients
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial
2. Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting
3. Virginia Tech Report Has National Importance
4. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
5. GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care
6. Haemacure Reports Third Quarter 2007 Results
7. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
8. Biotech Finishes on a High in August, Burrill Report Says
9. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
10. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
11. MDS Reports Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Takeda Pharmaceuticals Corp. has agreed to ... of Actos lawsuits ( http://www.theactoslawsuitcenter.com/ ) that allege ... a patient will develop bladder cancer. According to ... those eligible for the Actos settlement accept its terms, ... currently pending in courts around the country, including thousands ...
(Date:5/4/2015)... “ LiveSchool ” was featured on ... a look at the latest and coolest applications on ... the host of AppWatch and technology expert, conducted the ... allows teachers to reward students with good behavior. , ... in the classroom. And the good people at ...
(Date:5/4/2015)... 04, 2015 Baptist Medical Center ... Association’s Get With The Guidelines®-Stroke Gold Plus Quality ... Roll. The award recognizes the hospital’s commitment and ... most appropriate treatment according to nationally recognized, research-based ... To receive the Gold Plus Quality Achievement Award, ...
(Date:5/4/2015)... NY (PRWEB) May 04, 2015 Ticket Down ... 2015 International Champions Cup (ICC) . While the World ... and is held every four years, the International Champions Cup ... the tournament saw the all-time attendance record for soccer in ... from the Big House at the University of Michigan. This ...
(Date:5/4/2015)... 2015 Ticket Down is a reputable source ... Arena in Columbia, South Carolina. Fans of Paul ... “Out There” tour which originally kicked off in 2013. The ... America and the legendary performer recently announced that he would ... Arena on June 21st, in Charlottesville, VA at John Paul ...
Breaking Medicine News(10 mins):Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 2Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 3Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 4Health News:Paul McCartney Tickets at Colonial Life Arena in Columbia, SC: Ticket Down Slashes Paul McCartney Ticket Prices in Columbia, South Carolina at Colonial Life Arena 2
... turns off genes that keep tumors from forming, research shows ... insight into how a carcinogen in tobacco known as NNK ... at National Cheng Kung University in Taiwan report that NNK ... the nucleus of cells. In turn, DNMT1 turns off genes ...
... Obese patients can take steps to minimize risk, experts say ... of excess weight are well-known, such as heart disease, high ... obese patient is also a challenge for an anesthesiologist to ... our patients are obese," said Dr. Kumar Belani, a professor ...
... similar to MS in humans, findings show , TUESDAY, ... gene called ZFP191 causes central nervous system myelination problems ... humans with multiple sclerosis, new research has found. , ... and destroys the myelin sheath that insulates and protects ...
... ... nation’s leader in the fight against the disease ALS (amyotrophic laterals sclerosis) announced today ... , ... Calif. (Vocus) January 19, 2010 -- The ALS Association , the nation’s ...
... 11 A.M. , Justin Herman Plaza , ... , www.walkforlifewc.c o m , Speakers and organizers are ... A woman who walked away from her job as a clinic director ... intent on exposing abuses in the abortion industry will speak at the 6th Annual ...
... PORT-AU-PRINCE, Haiti , Jan. 19 One ... the challenges of delivering aid in the aftermath of the ... , Although aid is beginning to get through, the impact ... logistical challenges combined with a destroyed office and warehouse and ...
Cached Medicine News:Health News:Excess Weight Poses Anesthesia Challenge 2Health News:Excess Weight Poses Anesthesia Challenge 3Health News:Gordon S. LaVigne Appointed ALS Association Chief Development and Communications Officer , 2Health News:Gordon S. LaVigne Appointed ALS Association Chief Development and Communications Officer , 3Health News:6th Annual Walk for Life West Coast Saturday, January 23, 2010 2Health News:Haiti Earthquake: One Week Later, Aid Agencies Facing Challenges 2
(Date:5/4/2015)... 4, 2015 PAREXEL International Corporation (NASDAQ: PRXL ... UBS Healthcare Conference on Monday, May 18, 2015, in New ... Chief Financial Officer will be making a presentation on PAREXEL ... A live webcast of the presentation will be available through ... in the Upcoming Events portion of the main page, and ...
(Date:5/4/2015)... Pa. , May 4, 2015  Makindus, Inc. ... today that the European Medicines Agency (EMA) has granted ... the treatment of Stargardt,s Disease. "We are ... MI-100 to treat Stargardt,s disease in place for ... development program in the United States ...
(Date:5/4/2015)... BUFFALO, N.Y. , May 4, 2015 /PRNewswire/ ... Stephanie Englert , PharmD, has completed preliminary analysis ... Disorder and Schizophrenia. Resources from Clinical Support Services, ... Medication Reviews (CMR) with patients currently taking psychiatric ... events. The research found that 93% of patients ...
Breaking Medicine Technology:PAREXEL International to Present at UBS Healthcare Conference 2European Medicines Agency (EMA) Grants Orphan Designation for Makindus' MI-100 for Stargardt's Disease 2Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 2Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 3
300XL System, English (U.K. cord), 100-240 VAC....
Micro-mini fiber optic light....
Micro-mini fiber optic light....
The MC-3 allows for simultaneous use of two lamps, with an additional built-in spare....
Medicine Products: